GlaxoSmithKline Pharmaceuticals clears its cost of capital, but the record is mixed across the five tests. Real value creation, just not yet consistent.
GlaxoSmithKline Pharmaceuticals Limited engaging in the development, manufacture, and marketing of pharmaceutical products.
Business Segments.
The Company operations into a singular reportable segment categorized as Pharmaceuticals. This classifica…
Analysis
Quality compounder
GlaxoSmithKline Pharmaceuticals Limited is a quality compounder: a well-run business trading at a price that reflects what it is worth. One caution: reported profits have recently run ahead of actual cash, which we track closely.
The price is expensive. You pay 32.1× its owner earnings: the cash an owner could take out each year, which is in the historically expensive zone.
The trajectory is moderate and the balance sheet is sturdy. The company scores 13/20 on our value-creation score: creating some value. Analyst sentiment is cautious.
What to watch: Reported profits have run ahead of actual cash for several periods. As always: this describes the company's numbers; it is not a recommendation.
360° rank · history
1007550250
Jan 20235
8
2023202420252026
All-time high
79
Jan 2025
All-time low
5
Jan 2023
Average rank
32
across all years
Detailed & Historical Ranks
Deep dive into 15 detailed ranks and 3 years of history.
Current202520242023
Price/Sales
23
1
12
16
Price/Earnings
9
19
12
20
Price/Book
7
5
10
7
Dividend Yield
53
56
74
76
Value (overall)
5
13
17
29
Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.